Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 23,800 shares, a decrease of 38.0% from the November 15th total of 38,400 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 347,900 shares, the days-to-cover ratio is presently 0.1 days.
Institutional Investors Weigh In On Scopus BioPharma
A hedge fund recently raised its stake in Scopus BioPharma stock. Renaissance Technologies LLC boosted its holdings in Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,523 shares of the company's stock after buying an additional 91,623 shares during the quarter. Renaissance Technologies LLC owned approximately 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent reporting period. 3.26% of the stock is owned by institutional investors.
Get Scopus BioPharma alerts:Scopus BioPharma Price Performance
Shares of NASDAQ:SCPS traded up $0.11 on Thursday, hitting $0.34. The company had a trading volume of 31,236,390 shares, compared to its average volume of 355,100. The stock has a 50 day moving average price of $0.25 and a 200 day moving average price of $0.33. Scopus BioPharma has a 1-year low of $0.17 and a 1-year high of $2.11.
About Scopus BioPharma
(Get Rating)
Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
Read More
- Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
